Extracellular vesicle delivery of myristoylated Cas9 highlights chromatin accessibility as an efficacy barrier in prostate cancer.

Wang, S. (2026). Extracellular vesicle delivery of myristoylated Cas9 highlights chromatin accessibility as an efficacy barrier in prostate cancer.. Molecular Therapy : The Journal of the American Society of Gene Therapy, 34(1), 16-18.